Trial Profile

Open-Label Extension of the Halt Cardiomyopathy Progression in Duchenne (HOPE-Duchenne) Trial (CAP-1002-DMD-03)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2024 According to a Capricor Therapeutics media release, company will present its latest update of the HOPE-2 open label extension (OLE) 36-month data, both skeletal and cardiac, at the upcoming Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference being held June 27-29, 2024.
24 Apr 2024 According to a Capricor Therapeutics media release, company plans to share with FDA its HOPE-2 open label extension 3- year safety and efficacy data which is expected to be available in the second quarter of 2024 as part of Capricor's ISS and ISE strategy.
15 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com